UK health department asks for more time for Oxford COVID-19 vaccine review

2 min read | December 29, 2020 07:07 AM PST | By Team Kalkine Media

Google News:

Recent News

Cigna Adjusts Coverage Decisions Across Its Health Operations

Steel Dynamics Draws Attention With Record Shipments

Southern Company Serves A Data Center Hotspot

Vistra Sits In The Path Of Rising Electricity Demand

Make Kalkine Media
My Trusted Source

The UK Health Department has said that medical regulator MHRA needs some more time to review the data of the Oxford-AstraZeneca coronavirus vaccine.

A few days ago, it was reported that the vaccines would be rolled out across the country from 4 January.

Mass vaccination centres at conference venues and sports stadiums were scheduled for the next fortnight.

It was said that an emergency use authorisation could be forthcoming, and the vaccine could roll out to nations masses by early next week.

Now, a spokesperson from the UK health department has said that MHRA should be given the time to carry out its vital work and we should wait for its recommendation.

The government has ordered 100 million jabs of the Oxford vaccine, where 40 million doses are scheduled to reach by March next year.

Its worth noting that the US has entered a contract with the company for 300 million doses of the vaccine, much higher than the orders given to the already permitted Moderna's and Pfizer-BioNTech's vaccines.

Meanwhile, Pascal Soriot, AstraZeneca CEO has reportedly said that he thinks that the later trials will show that the vaccine is 95 per cent effective against COVID-19 infections.

On 29 December 2020, the stocks of the AstraZeneca Plc (LON:AZN) traded higher by 3.21% from its previous closing, hovering at around GBX 7,455.00at 14:39 PM GMT+1.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.